Digital breast tomosynthesis (DBT), a form of supplemental screening mammography, is not recommended for routine screening in any clinical practice guidelines. Nevertheless, a study by Richman et al1 in this issue of JAMA Internal Medicine shows that it is widely used in the United States. Based on analyses of national Blue Cross Blue Shield claims data on screening mammography, Richman et al1 found that DBT use during screening increased from about 13% in 2015 to more than 40% in 2017. The uptake of DBT grew significantly faster in regions with higher income and larger white populations.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Melnikow J, Fenton JJ. Digital Breast Tomosynthesis—Diffusion Into Practice Preceding Evidence. JAMA Intern Med. Published online June 24, 2019. doi:10.1001/jamainternmed.2019.1037
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: